Group 1 - Genflow Biosciences Ltd experienced a nearly 20% increase in stock price following positive interim results from its aged dog trial, where treated dogs demonstrated improved survival and muscle health without any reported adverse events [1] - IXICO PLC secured an additional £1.5 million in contracted revenue from an extension of its Huntington's disease trial, with income to be recognized over three years as the company establishes repeat business with major pharmaceutical clients [1] Group 2 - Helium One Global Ltd announced that the Galactica-Pegasus helium plant in Colorado is set to commence integrated operations next week, transitioning from commissioning to ramp-up, with spot sales already agreed and ongoing contract negotiations [2] - Bellevue Healthcare Trust PLC is seeking Columbia Threadneedle to assume the role of investment manager, offering shareholders a full exit option at a 2% discount to net asset value [2]